Recce Pharmaceuticals (ASX:RCE) has received patent acceptance in China for its synthetic anti-infectives Recce 327 and Recce 529, with protection valid until 2041, according to a Monday filing with the Australian bourse.
The patent covers the manufacturing processes of the infectives and their use across a range of infections, including diabetic foot infections, pneumonia, and COVID-19, the filing said.
It also includes the administration of the infectives by various delivery methods, the filing added.
Shares of the company rose 2% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.